Antisoma's AS1411 gains US and EU Orphan Drug Status for acute myeloid leukaemia
Antisoma plc announces that its aptamer drug AS1411 has been granted orphan drug status in both the United States and the European Union for the treatment of acute myeloid leukaemia (AML). The grants will provide seven years of market exclusivity in the US and ten years of exclusivity in the EU if AS1411 is approved for use in AML.
Positive phase II data for AS1411 in AML were presented at the 2008 ASH and 2009 ASCO meetings. Addition of AS1411 to high-dose cytarabine increased response rates without significantly increasing side-effects in patients with relapsed or refractory AML. Phase IIb trials are now planned: the first is expected to start in early 2010. Should this yield positive findings, rapid progress into a registration trial is anticipated.
AS1411 already has orphan drug status in both the US and the EU for the treatment of renal cancer. A phase II trial in renal cancer is ongoing, and expected to report initial data before the end of this year.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Scientists discover a potential treatment for cirrhosis
Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214
Could viruses be used to treat acne?
Caffeine appears to be beneficial in males - but not females - with Lou Gehrig's disease
Researchers study the human factor in spread of pandemic illness

How CRISPR can help fight against neurodegenerative diseases - Scientists listed ways of applying genetic engineering to treat Parkinson's disease

Stem Cells May Speed Up Screening of Drugs for Rare Cancers

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus
Removab Approval: Proof-of-Concept for Technology Transfer in Germany

Decoding Blood Platelet Production: The Intricate Role of Lipids - Disruptions in lipid metabolism might affect platelet production

Excessive fluid consumption: habit or hormonal disorder? - Which test provides a reliable diagnosis?
